Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 6/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
| ▸ | KDM5C | P41229 | 1/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CSF1R | P07333 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26885910 | 0.97 | CXCR4 (0.46) | CXCR4KDM4EALDH1A1HIF1ASIGMAR1 | |
| SCHEMBL24384235 | 0.89 | CXCR4 (0.40) | CXCR4KDM4EALDH1A1HIF1APRMT5 | |
| SCHEMBL26090944 | 0.87 | CXCR4 (0.53) | CXCR4KDM4EALDH1A1HIF1ASIGMAR1 | |
| SCHEMBL24384168 | 0.80 | ALDH1A1 (0.47) | KDM4EALDH1A1LMNACHRM3 | |
| SCHEMBL26885893 | 0.80 | MEN1 (0.35) | CXCR4KDM4EALDH1A1HIF1AKDM5C | |
| SCHEMBL26885909 | 0.78 | ALDH1A1 (0.44) | KDM4EALDH1A1LMNACHRM3 | |
| SCHEMBL26885911 | 0.76 | KDM4E (0.36) | KDM4ELMNA | |
| SCHEMBL17348027 | 0.76 | MELK (0.36) | CHRM3 | |
| SCHEMBL19975605 | 0.74 | KDM5C (0.38) | KDM4EALDH1A1SIGMAR1PRMT5KDM5C | |
| SCHEMBL26885976 | 0.73 | MEN1 (0.35) | KDM5CKDM4CCHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382928-A1 | EUROPIUM(III) COMPLEXES AS PH SENSORS | CISBIO BIOASSAYS (FR) | 2023-11-30 | — | — | US | disclosed |
| WO-2022090284-A1 | EUROPIUM(III) COMPLEXES AS PH SENSORS | CISBIO BIOASSAYS (FR) | 2022-05-05 | — | — | WO | disclosed |
| EP-3992182-A1 | EUROPIUM(III) COMPLEXES AS PH SENSORS | Cisbio Bioassays (FR) | 2022-05-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382928-A1 | EUROPIUM(III) COMPLEXES AS PH SENSORS | NCS1, GALR3, TAS1R3 | CXCR4 1190/4885KDM4E 3023/4885ALDH1A1 3455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.